Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence-Reference-Cited by-同舟云学术

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Published:2024-08-07 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Martinez-Lopez J.^ORCID,Lopez-Muñoz N.^ORCID,Chari A.^ORCID,Dorado S.^ORCID,Barrio S.,Arora S.,Kumar A.,Chung A.,Martin T.^ORCID,Wolf J.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01102-x.pdf

Reference18 articles.

1. Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422–32.

2. Paiva B, García-Sanz R, San Miguel JF. Multiple myeloma minimal residual disease. En: Roccaro AM, Ghobrial IM, editores. Plasma Cell Dyscrasias [Internet]. Cham: Springer International Publishing; 2016 [citado 25 de octubre de 2023]. p. 103–22 (Cancer treatment and research, vol. 169). Disponible en: http://link.springer.com/10.1007/978-3-319-40320-5_7

3. Yang PY, Liu MM, Fan HQ, Yang YP, Han W, Yu XY. et al. The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma. Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi. 2019;40:584–8.

4. Yang GZ, Wang GR, Wang HJ, Zhang YR, Wu Y, Li YC. et al. The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era. Zhonghua Yi Xue Za Zhi. 2022;102:2345–50.

5. Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4:3295–301.